Takeda's legacy in oncology extends more than 25 years and includes a range of paradigm-changing therapies for hematologic cancers and solid tumors. Our research and development (R&D) efforts are focused on compounds are that either unprecedented in their approach or offer a best-in-class advantage. This higher-powered level of scientific endeavor demands personal determination on the part of our scientists and an open-mindedness to embrace innovation and to reject conventional wisdom.
Today, our research includes investigating the utility of brentuximab vedotin in Hodgkin lymphoma and other lymphoid malignancies and the utility of ixazomib in multiple myeloma and systemic light-chain amyloidosis. Learn more about R&D at Takeda.
Our oncology platform capabilities encompass small molecules, antibodies and antibody drug conjugates (ADCs). Building off the success of bortezomib, Takeda has deep drug discovery expertise in protein homeostasis, which has expanded to other novel areas of biology relevant in cancer. The current development portfolio is representative of this expertise, combined with a strengthening footprint in therapeutic biologics as well as differentiated and potentially best in class cell signaling inhibitors.
Takeda has a promising early pipeline targeting a wide range of cancers. Learn more about our pipeline.
"Our Oncology R&D organization represents a global effort, with our Oncology discovery and development centered in Cambridge, San Diego, London, Tokyo and at the Shonan Research Center in Japan. We have formed a number of novel partnerships with innovative companies, research institutes and academic hospitals and are committed to seeking out more. As a result, our oncology R&D infrastructure is focused on developing innovative products that improve patient lives."Phil Rowlands
Ad Interim Head, Oncology Therapeutic Area Unit